{"title":"功能失调的肠道微血管内皮细胞:胃肠道炎症的启示和治疗意义。","authors":"Ji Seok Park, Gail A M Cresci","doi":"10.1097/IN9.0000000000000043","DOIUrl":null,"url":null,"abstract":"<p><p>The intestinal microvascular endothelium plays a crucial role in orchestrating host responses to inflammation within the gastrointestinal tract. This review delves into the unique aspects of intestinal microvascular endothelial cells, distinct from those of larger vessels, in mediating leukocyte recruitment, maintaining barrier integrity, and regulating angiogenesis during inflammation. Specifically, their role in the pathogenesis of inflammatory bowel diseases, where dysregulated endothelial functions contribute to the disease progression, is reviewed. Furthermore, this review discusses the isolation technique for these cells and commonly used adhesion molecules for in vitro and in vivo experiments. In addition, we reviewed the development and therapeutic implications of a biologic agent targeting the interaction between α<sub>4</sub>β<sub>7</sub> integrin on T lymphocytes and mucosal addressin cellular adhesion molecule-1 on gut endothelium. Notably, vedolizumab, a humanized monoclonal antibody against α<sub>4</sub>β<sub>7</sub> integrin, has shown promising outcomes in inflammatory bowel diseases and other gastrointestinal inflammatory conditions, including chronic pouchitis, immune checkpoint inhibitor-induced colitis, and acute cellular rejection post-intestinal transplantation.</p>","PeriodicalId":73349,"journal":{"name":"Immunometabolism (Cobham (Surrey, England))","volume":"6 2","pages":"e00043"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11136270/pdf/","citationCount":"0","resultStr":"{\"title\":\"Dysfunctional intestinal microvascular endothelial cells: Insights and therapeutic implications in gastrointestinal inflammation.\",\"authors\":\"Ji Seok Park, Gail A M Cresci\",\"doi\":\"10.1097/IN9.0000000000000043\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The intestinal microvascular endothelium plays a crucial role in orchestrating host responses to inflammation within the gastrointestinal tract. This review delves into the unique aspects of intestinal microvascular endothelial cells, distinct from those of larger vessels, in mediating leukocyte recruitment, maintaining barrier integrity, and regulating angiogenesis during inflammation. Specifically, their role in the pathogenesis of inflammatory bowel diseases, where dysregulated endothelial functions contribute to the disease progression, is reviewed. Furthermore, this review discusses the isolation technique for these cells and commonly used adhesion molecules for in vitro and in vivo experiments. In addition, we reviewed the development and therapeutic implications of a biologic agent targeting the interaction between α<sub>4</sub>β<sub>7</sub> integrin on T lymphocytes and mucosal addressin cellular adhesion molecule-1 on gut endothelium. Notably, vedolizumab, a humanized monoclonal antibody against α<sub>4</sub>β<sub>7</sub> integrin, has shown promising outcomes in inflammatory bowel diseases and other gastrointestinal inflammatory conditions, including chronic pouchitis, immune checkpoint inhibitor-induced colitis, and acute cellular rejection post-intestinal transplantation.</p>\",\"PeriodicalId\":73349,\"journal\":{\"name\":\"Immunometabolism (Cobham (Surrey, England))\",\"volume\":\"6 2\",\"pages\":\"e00043\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11136270/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunometabolism (Cobham (Surrey, England))\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/IN9.0000000000000043\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/4/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunometabolism (Cobham (Surrey, England))","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/IN9.0000000000000043","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
肠道微血管内皮细胞在协调宿主对胃肠道炎症的反应方面发挥着至关重要的作用。这篇综述深入探讨了肠道微血管内皮细胞在炎症期间介导白细胞招募、维持屏障完整性和调节血管生成方面的独特之处,它们与大血管内皮细胞不同。具体而言,本研究综述了它们在炎症性肠病发病机制中的作用,其中内皮功能失调导致了疾病的进展。此外,本综述还讨论了这些细胞的分离技术以及用于体外和体内实验的常用粘附分子。此外,我们还综述了针对 T 淋巴细胞上的α4β7 整合素与肠道内皮细胞上的粘膜地址素细胞粘附分子-1 之间相互作用的生物制剂的开发和治疗意义。值得注意的是,vedolizumab 是一种针对 α4β7 整合素的人源化单克隆抗体,在炎症性肠病和其他胃肠道炎症(包括慢性肠袋炎、免疫检查点抑制剂诱导的结肠炎和肠道移植后的急性细胞排斥反应)方面显示出良好的疗效。
Dysfunctional intestinal microvascular endothelial cells: Insights and therapeutic implications in gastrointestinal inflammation.
The intestinal microvascular endothelium plays a crucial role in orchestrating host responses to inflammation within the gastrointestinal tract. This review delves into the unique aspects of intestinal microvascular endothelial cells, distinct from those of larger vessels, in mediating leukocyte recruitment, maintaining barrier integrity, and regulating angiogenesis during inflammation. Specifically, their role in the pathogenesis of inflammatory bowel diseases, where dysregulated endothelial functions contribute to the disease progression, is reviewed. Furthermore, this review discusses the isolation technique for these cells and commonly used adhesion molecules for in vitro and in vivo experiments. In addition, we reviewed the development and therapeutic implications of a biologic agent targeting the interaction between α4β7 integrin on T lymphocytes and mucosal addressin cellular adhesion molecule-1 on gut endothelium. Notably, vedolizumab, a humanized monoclonal antibody against α4β7 integrin, has shown promising outcomes in inflammatory bowel diseases and other gastrointestinal inflammatory conditions, including chronic pouchitis, immune checkpoint inhibitor-induced colitis, and acute cellular rejection post-intestinal transplantation.